Medi Caps
BSE: MEDICAPQ · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Medi Caps's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Medi Caps Limited is an Indian manufacturer specialising in empty hard gelatin capsules for the pharmaceutical and nutraceutical sectors. The company also maintains diversified interests in real estate and infrastructure development.
Business Model
The company generates revenue through the large-scale production and sale of various capsule sizes and types, including fortified and liquid-fill options. It further supplements its income through project-based activities in the real estate and infrastructure sectors.
Growth Outlook
Growth is driven by the company's ability to supply essential packaging solutions to the expanding domestic and international pharmaceutical markets. Continued investment in automated production lines aims to maintain compliance with global quality standards.
Key Risks
- Raw Material Price Volatility. Fluctuations in the cost of gelatin and other raw materials can significantly impact manufacturing margins.
- Regulatory Compliance. Failure to adhere to stringent global pharmaceutical quality standards could lead to loss of market access or reputational damage.
- Real Estate Market Cyclicality. The company's diversification into real estate exposes it to the inherent volatility and capital-intensive nature of the property development sector.
- Competitive Pressure. The capsule manufacturing industry is highly competitive, potentially leading to pricing pressures from both domestic and international players.
Start your research today
Unlock AI insights, financials, peers and live data on Medi Caps and 5,000+ companies — free.
Key Metrics
REVENUE
₹12 Cr
TTM · consolidated
NET PROFIT
₹9 Cr
TTM · consolidated
EPS
₹7.31
TTM · consolidated
RETURN ON EQUITY
7.7%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
7.6%
TTM · consolidated
P/E
3.7x
Q4 FY26 · consolidated
EV/EBITDA
2.9x
Q4 FY26 · consolidated
EBITDA MARGIN
87.6%
TTM · consolidated
NET PROFIT MARGIN
88.1%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.0x
Q4 FY26 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Medi CapsMEDICAPQ | ₹32 Cr | 3.54 | 2.92 | -51.1% | 87.6% | 7.7% | 7.6% | -35.3% |
Albert DavidALBERTDAVD | ₹513 Cr | 22.73 | 13.48 | 11.4% | 11.0% | 5.8% | 7.5% | +12.1% |
Jenburkt Pharmaceuticals LimitedJENBURPH | ₹463 Cr | 13.31 | 8.46 | — | 32.0% | 17.6% | 23.2% | -4.3% |
Haleos Labs LimitedHALEOSLABS | ₹452 Cr | 28.60 | 12.72 | -3.1% | 13.6% | 7.4% | 10.3% | — |
TranschemTRANSCHEM | ₹424 Cr | 98.76 | 68.07 | -100.0% | 177.7% | 5.3% | 7.0% | +592.6% |
Medicamen BiotecMEDICAMEQ | ₹338 Cr | 33.59 | 15.53 | 24.7% | 11.3% | 4.1% | 6.2% | -27.9% |
As of Q4 FY26
Financials
Medi Caps
BSE: MEDICAPQ · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Medi Caps's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Medi Caps Limited is an Indian manufacturer specialising in empty hard gelatin capsules for the pharmaceutical and nutraceutical sectors. The company also maintains diversified interests in real estate and infrastructure development.
Business Model
The company generates revenue through the large-scale production and sale of various capsule sizes and types, including fortified and liquid-fill options. It further supplements its income through project-based activities in the real estate and infrastructure sectors.
Growth Outlook
Growth is driven by the company's ability to supply essential packaging solutions to the expanding domestic and international pharmaceutical markets. Continued investment in automated production lines aims to maintain compliance with global quality standards.
Key Risks
- Raw Material Price Volatility. Fluctuations in the cost of gelatin and other raw materials can significantly impact manufacturing margins.
- Regulatory Compliance. Failure to adhere to stringent global pharmaceutical quality standards could lead to loss of market access or reputational damage.
- Real Estate Market Cyclicality. The company's diversification into real estate exposes it to the inherent volatility and capital-intensive nature of the property development sector.
- Competitive Pressure. The capsule manufacturing industry is highly competitive, potentially leading to pricing pressures from both domestic and international players.
Start your research today
Unlock AI insights, financials, peers and live data on Medi Caps and 5,000+ companies — free.
Key Metrics
REVENUE
₹12 Cr
TTM · consolidated
NET PROFIT
₹9 Cr
TTM · consolidated
EPS
₹7.31
TTM · consolidated
RETURN ON EQUITY
7.7%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
7.6%
TTM · consolidated
P/E
3.7x
Q4 FY26 · consolidated
EV/EBITDA
2.9x
Q4 FY26 · consolidated
EBITDA MARGIN
87.6%
TTM · consolidated
NET PROFIT MARGIN
88.1%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.0x
Q4 FY26 · consolidated
Peers · Pharmaceuticals
As of Q4 FY26